Induction Chemotherapy and Chemoradiation Therapy for Inoperable Locally Advanced Non–Small-Cell Lung Cancer: A Single-Institution Review of Two Different Regimens
| Autor: | Mihriban Kocak, Makbule Eren, A. Ozkan, Sule Gul Karabulut, Fatih Oruc, Ahmet Bilici, Mesut Seker, Cem Parlak, Alpaslan Mayadagli, Mahmut Gumus, Bala Basak Oven Ustaalioglu |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Docetaxel Adenocarcinoma Neutropenia Deoxycytidine Gastroenterology Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Lung cancer Aged Neoplasm Staging Cisplatin business.industry Remission Induction Induction chemotherapy Radiotherapy Dosage Middle Aged Prognosis medicine.disease Combined Modality Therapy Gemcitabine Survival Rate Radiation therapy Treatment Outcome Carcinoma Squamous Cell Female Taxoids business Esophagitis Follow-Up Studies medicine.drug |
| Zdroj: | Clinical Lung Cancer. 10:124-129 |
| ISSN: | 1525-7304 |
| Popis: | Purpose We compared 2 different chemotherapeutic agents in combination with cisplatin as induction chemotherapy (ICT) followed by chemoradiation therapy (CHRT) in patients with inoperable locally advanced non–small-cell lung cancer (NSCLC). Patients and Methods A total of 90 patients with inoperable locally advanced NSCLC received 3 courses of ICT consisting of gemcitabine 1200 mg/m 2 on day 1 and day 8 every 3 weeks and cisplatin 75 mg/m 2 on day 1 every 3 weeks (group 1; n=39) or docetaxel 75 mg/m 2 on day 1 every 3 weeks and cisplatin 75 mg/m 2 on day 1 every 3 weeks (group 2; n=51) followed by CHRT (docetaxel 30 mg/m 2 every week and cisplatin 20 mg/m 2 every week with 6600 cGy radiation therapy). Results After the ICT, the response rate for group 2 (88.2%) was significantly higher than that of the gemcitabine-cisplatin arm (64.1%; P = .017). The response assessment performed on first month after CHRT revealed statistical difference for objective response rate in group 2 when compared with group 1 ( P = .04). At the median follow-up of 15.7 months (range, 5-36 months), median overall survival (OS) was 12 months in group 1 (95% CI, 9.1-14.8) and 29.9 months in group 2 (95% CI, 16-43). Median progression-free survival (PFS) was 8 months in group 1 and 15 months in group 2. There was statistically significant difference between the 2 groups regarding OS and PFS ( P = .043). Conclusion Our results suggest that OS, PFS, and local control rate are significantly improved with ICT consisting of docetaxel and cisplatin when compared with gemcitabine-cisplatin in inoperable locally advanced NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect